Truist Financial Corp Myovant Sciences Ltd. Transaction History

Truist Financial Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$11.38 - $16.4 $1.92 Million - $2.76 Million	-168,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $643,950 - $1.07 Million	-45,000 Reduced 21.08%	168,500 $2.62 Million
Q3 2021 Nov 05, 2021	SELL	$18.94 - $26.99 $1,553 - $2,213	-82 Reduced 0.04%	213,500 $4.79 Million
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $1.08 Million - $1.55 Million	63,082 Added 41.91%	213,582 $4.86 Million
Q1 2021 May 17, 2021	BUY	$20.46 - $25.18 $501,270 - $616,910	24,500 Added 19.44%	150,500 $3.1 Million
Q4 2020 Feb 18, 2021	BUY	$13.8 - $27.62 $1.2 Million - $2.4 Million	87,000 Added 223.08%	126,000 $3.48 Million
Q3 2020 Nov 13, 2020	BUY	$14.05 - $22.6 $182,650 - $293,800	13,000 Added 50.0%	39,000 $548,000
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $190,840 - $541,840	26,000 New	26,000 $536,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.